Overview

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is: 1. To establish the maximally tolerated dose (MTD) of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. 2. To evaluate disease free and overall survival after this conditioning regimen in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 3. To evaluate potential pharmacogenomic determinants of toxicity of this regimen. 4. To evaluate potential pharmacogenomic determinants of efficacy of this regimen.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Chicago

Treatments:

Alemtuzumab
Busulfan
Fludarabine
Fludarabine phosphate
Vidarabine